Physician profile
Diane M Glendinning
NPI 1710253612
$26,195.93
in general payments reported to CMS, 2019-2025
41 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $361 · 2023: $526 · 2024: $698 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $3,560 · Food and Beverage: $2,065 · Consulting Fee: $870 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,615.00 |
| Travel and Lodging | $3,560.08 |
| Food and Beverage | $2,065.19 |
| Consulting Fee | $870.00 |
| Education | $295.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $24,481.40 | 2021-2025 | Carvykti, Rybrevant, Darzalex |
| Janssen Scientific Affairs, LLC | $193.17 | 2021-2024 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $156.04 | 2022-2023 | Opdualag |
| Novartis Pharmaceuticals Corporation | $130.02 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $116.57 | 2021-2023 | |
| Genzyme Corporation | $100.17 | 2021-2025 | |
| Seagen INC. | $81.99 | 2023 | |
| Eisai INC. | $68.28 | 2022-2024 | |
| Genmab U.S., INC. | $63.48 | 2023-2025 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $59.60 | 2023-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $59.58 | 2021-2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $53.67 | 2021-2024 | Ninlaro |
| Jazz Pharmaceuticals INC. | $51.75 | 2021-2024 | |
| Exelixis INC. | $50.09 | 2022-2024 | Cabometyx |
| Pfizer INC. | $43.56 | 2024-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Glendinning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.